North Charleston, South Carolina - October 4, 2005 - Argolyn Bioscience, a biopharmaceutical company in North Charleston, South Carolina, announced today that it has added David Feifel MD PhD as a Translational Research Consultant and the newest member of its Scientific Advisory Board.

Dr. Feifel is an Associate Professor in Residence in the Department of Psychiatry at the University of California, San Diego where his neuropsychopharmacology laboratory develops animal models to explore the biological mechanisms of psychiatric disease and potential novel therapeutics focusing on neuropeptide-based treatments. Dr. Feifel has done some of the fundamental preclinical work establishing the therapeutic potential of drugs that target neurotensin receptors. Argolyn's lead compound is a derivative of a neurotensin receptor agonist.

In addition to his basic neuropsychopharmacology research, Dr. Feifel also heads a clinical neuropharmacology research program at UCSD Medical Center which evaluates the safety and efficacy of approved and investigational psychotropic medications. Dr. Feifel is the Director of the Adult Psychiatric Services at the UCSD Medical Center and Senior Attending Psychiatrist for the Neuropsychiatry and Behavioral Inpatient Unit.

"David is such a great match for Argolyn on so many levels," said Argolyn Chief Scientific Officer, Tom Dix, Ph.D., who also chairs Argolyn's Scientific Advisory Board and on whose inventions Argolyn Bioscience was founded. "First, David adds important clinical neuropharmacology expertise at a time when Argolyn is rapidly advancing toward human clinical trials with its lead antipsychotic compound. Second, David brings unique and profound insight into how the Argolyn technology can be applied to the development of other neuropeptides as therapeutic entities for a wide range of neuropsychiatric and neurodegenerative diseases. Finally, as a rising star in his field, David gives Argolyn very creditable exposure to the academic, financial, and industrial biotech communities on the West Coast. Argolyn is extremely fortunate to add him to our team."

Argolyn Bioscience Inc.

Argolyn Bioscience Inc. is a peptide product development company headquartered in North Charleston, South Carolina. Argolyn is the exclusive worldwide licensee for a portfolio of patents and patent applications aimed at improving the pharmacology of peptide drug candidates. The company has one product in preclinical development and several other discovery stage product programs. Argolyn Bioscience continues to seek other opportunities to disseminate the technology either through collaboration or out-licensing. For more information, contact the company or visit the website at www.argolyn.com.

Contact:
Pearce Gilbert
Argolyn Bioscience Inc.
Tel: (843) 266-0851
Fax: (843) 266-0894
info@argolyn.com